Today: 29 December 2025
Subscribe

Disney Stock (DIS) Outlook on Dec. 20, 2025: OpenAI Deal, ESPN Streaming Momentum, and Parks Pricing Power Put Shares Back in Focus

Disney Stock (DIS) Outlook on Dec. 20, 2025: OpenAI Deal, ESPN Streaming Momentum, and Parks Pricing Power Put Shares Back in Focus

Disney stock is ending 2025 at a crossroads that looks familiar—and newly disruptive at the same time. On one hand, the Walt Disney Company’s legacy businesses are still navigating structural pressure: cord-cutting continues to erode the traditional TV bundle, and
21 December 2025
·····
Gold Price Today (December 20, 2025): MCX Gold Rebounds, Silver Slips After Record High — Latest 24K, 22K Rates in Delhi, Mumbai, Jaipur and Udaipur

Gold Price Today (December 20, 2025): MCX Gold Rebounds, Silver Slips After Record High — Latest 24K, 22K Rates in Delhi, Mumbai, Jaipur and Udaipur

Gold and silver prices remained volatile on December 20, 2025. MCX gold futures recovered sharply, while silver cooled off after touching a fresh record. Here’s a detailed, city-wise look at today’s 24K and 22K gold rates, silver prices, and what’s
21 December 2025
····
NextEra Energy Stock (NEE) in Focus: AI Data Center Deals, 2026 Earnings Outlook, and Wall Street Price Targets — Dec. 20, 2025

NextEra Energy Stock (NEE) in Focus: AI Data Center Deals, 2026 Earnings Outlook, and Wall Street Price Targets — Dec. 20, 2025

NextEra Energy, Inc. (NYSE: NEE) is ending 2025 with a familiar role—and a new narrative. For years, investors have treated NextEra as a premium “growth utility,” built on Florida Power & Light’s regulated stability and NextEra Energy Resources’ renewables scale.
21 December 2025
·····
Vertex Pharmaceuticals (VRTX) Stock News, Forecasts and Analyst Outlook on Dec. 20, 2025: Casgevy Pediatric Data, Kidney Pipeline Momentum, and Journavx Launch Watch

Vertex Pharmaceuticals (VRTX) Stock News, Forecasts and Analyst Outlook on Dec. 20, 2025: Casgevy Pediatric Data, Kidney Pipeline Momentum, and Journavx Launch Watch

December 20, 2025 — Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) heads into the year’s final stretch with investors focused on a familiar question: can the biotech’s next wave of launches and late-stage programs begin to meaningfully diversify a cystic fibrosis (CF)
21 December 2025
·····
1 … 227 228 229 230 231 … 1,574
Go toTop